培美曲塞联合卡铂治疗老年晚期非小细胞肺癌疗效观察

目的 探讨培美曲塞联合卡铂治疗老年晚期非小细胞肺癌的临床疗效.方法 将60例老年晚期非小细胞肺癌患者按数字表法随机分为对照组和观察组,各30例.观察组采用培美曲塞联合卡铂治疗,而对照组采用吉西他滨联合卡铂治疗.比较两组临床疗效、肿瘤进展时间、一年生存率以及不良反应发生情况.结果 两组有效率差异无统计学意义（χ^2=0.38,P〉0.05）;观察组肿瘤进展时间、一年生存率分别为（5.9±1.6）个月、50.0%,与对照组的（5.7±1.1）个月、53.3%差异均无统计学意义（t=0.39,χ^2=1.20,均P〉0.05）;观察组血液学毒性、消化道毒性发生率、其他并发症分别为20.0%、20.0%、13.3%,明显低于对照组的46.7%、66.7%、40.0%（χ^2=4.28、5.41、5.32,均P〈0.05）.结论 采用培美曲塞联合卡铂治疗老年晚期非小细胞肺癌患者具有十分显著的疗效,可明显延长患者的生存期,毒副反应轻微,是老年患者较佳的治疗措施.

Observation of the effect of pemetrexed combined with carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer

Objective T0 investigate the clinical efficacy of pemetrexed combined with carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Methods According to the digital table,60 elderly patients with advanced non-small cell lung cancer were divided into the observation group and the control group ,30 cases in each group. The observation group was given pemetrexed plus carboplatin, and the control group was given gemcitabine and carboplatin. The clinical efficacy, time of tumor progression, one-year survival rate and adverse events of two groups were compared. Results The effective rate had no significant difference between the two groups （X^2 = 0.38, P 〉 0.05 ）. The time of tumor progression, one-year survival rate of the observation group were （5.9 ± 1.6） months,50.0% ,respectively,which were not significantly different with those of the control group （5.7 ± 1.1 ） months, 53.3 % ] （ t = 0.39, X^2 = 1.20, all P 〉 0.05 ）. The incidence rates of hematologic toxicity, gastrointestinal toxicity,other complications in observation group were 20.0%, 20.0%, 13.3%, which were significantly lower than those of the control group （46.7%, 66.7% ,40.0% ） （ X^2 = 4.28,5.41,5.32, all P 〈 0.05 ）. Conclusion Pemetrexed combined with carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer has significant effect.